SCHEMBL368647

SCHEMBL368647

CCC(O)c1nn(Cc2ccc(OC)cc2)cc1-c1nc(Nc2ncc(F)cn2)sc1CO

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.34
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
GLA P06280 1/20 0.33
CYP2C9 P11712 1/20 0.33
TSHR P16473 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HIF1A Q16665 1/20 0.33
FYN P06241 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
HDAC1 Q13547 2/20 0.31
JAK3 P52333 1/20 0.31
MAPT P10636 3/20 0.31
GAA P10253 2/20 0.30
PTGDR2 Q9Y5Y4 2/20 0.30
CRHR1 P34998 1/20 0.30
EIF2AK4 Q9P2K8 1/20 0.30
MET P08581 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL369702 0.86 HDAC1 (0.32) MEN1KMT2AHDAC1MAPTGAA
SCHEMBL370913 0.86 ACHE (0.36) ACHEALDH1A1LMNAGLACYP2C9
SCHEMBL370777 0.81 MEN1 (0.36) ALDH1A1LMNAMEN1KMT2AHDAC1
SCHEMBL370255 0.75 DHODH (0.44) ALDH1A1LMNAMEN1KMT2AMAPT
SCHEMBL6837469 0.73 GRM4 (0.40) ACHEALDH1A1LMNAMEN1KMT2A
SCHEMBL6837141 0.73 ACHE (0.35) ACHEALDH1A1LMNAGLACYP2C9
SCHEMBL15182520 0.72 MEN1 (0.38) ALDH1A1LMNAMEN1KMT2AHDAC1
SCHEMBL366145 0.72 ACHE (0.36) ACHEMEN1KMT2AMAPT
SCHEMBL368225 0.72 ACHE (0.37) ACHEALDH1A1LMNAGLACYP2C9
SCHEMBL15303272 0.72 GRM4 (0.37) ACHEALDH1A1LMNAGLACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 ACHE 1201/4885ALDH1A1 3331/4885LMNA 4688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.